Leader in Genomic Sequencing Illuminates the Way
Continued technology advancements and market expansion support Illumina's narrow moat.
As the current leader in genomic sequencing, Illumina (ILMN) faces an impressive growth opportunity as the emergence of this technology creates new applications while also potentially disrupting many existing genetic research and clinical diagnostic markets. Accelerating demand for Illumina's products combined with operating leverage potential should sustain high earnings growth.
Although Illumina management's preview of 20% revenue growth and adjusted earnings per share of $3.12-$3.18 for 2015 falls modestly below our expectations, we don't anticipate any change to our fair value estimate at this time. Management has a history of kicking off the new fiscal year with a conservative tone, and we think new product announcements, including the next evolution of HiSeq instruments, along with ongoing strong equipment and consumables sales among all instrument product lines should enable Illumina to outpace 20% growth during 2015. Additionally, Illumina will begin selling the HiSeq X in a smaller five-instrument bundle, which should continue to expand the market in this highest-throughput category. Despite management's somewhat subdued growth outlook, the company expects gross margin near 73% in 2015, which is considerably healthier than our prediction. Although the evolution of the genome sequencing market remains uncertain, especially in the clinical prenatal testing and oncology fields, we think Illumina's technology advancements continue to support its narrow economic moat.
Michael Waterhouse does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.